HUP0102203A2 - Optikailag tiszta (+)-norciszaprid alkalmazása apnoé, bulimia és más rendellenességek kezelésére alkalmas gyógyászati készítmények előállítására - Google Patents

Optikailag tiszta (+)-norciszaprid alkalmazása apnoé, bulimia és más rendellenességek kezelésére alkalmas gyógyászati készítmények előállítására

Info

Publication number
HUP0102203A2
HUP0102203A2 HU0102203A HUP0102203A HUP0102203A2 HU P0102203 A2 HUP0102203 A2 HU P0102203A2 HU 0102203 A HU0102203 A HU 0102203A HU P0102203 A HUP0102203 A HU P0102203A HU P0102203 A2 HUP0102203 A2 HU P0102203A2
Authority
HU
Hungary
Prior art keywords
norcisapride
optically pure
bulimia
disorders
pharmaceutical compositions
Prior art date
Application number
HU0102203A
Other languages
English (en)
Inventor
Timothy J. Barberich
Paul D. Rubin
Original Assignee
Sepracor Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc. filed Critical Sepracor Inc.
Publication of HUP0102203A2 publication Critical patent/HUP0102203A2/hu
Publication of HUP0102203A3 publication Critical patent/HUP0102203A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány optikailag tiszta (+)-norciszapridnak, kémiai nevén 4-amino-5-klór-N-(3-metoxi-4-piperidinil)-2-metoxibenzamidnak, aciszaprid, azaz a cisz-4-amino-5-klór-N-(1-[3-(4-fluor-fenoxi)propil]-3-metoxi-4-piperidinil}-2-metoxibenzamid metabolitjának azalkalmazására vonatkozik apnoé, bulimia és rokon rendellenességek vagyazok tüneteinek megelőzésére, kezelésére vagy kézbentartására alkalmasgyógyászati készítmények előállítására. Az optikailag tiszta (+)-norciszaprid alkalmazása esetén káros mellékhatások csak kis mértékbenvagy nem lépnek fel, és lehetővé válik a beteg más gyógyszerekkeltörténő párhuzamos kezelése is. Ó
HU0102203A 1998-06-15 1999-06-10 Use of optically pure(+)-norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimia and other disorders HUP0102203A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8922498P 1998-06-15 1998-06-15
US12227599P 1999-03-01 1999-03-01
PCT/US1999/013099 WO1999065571A2 (en) 1998-06-15 1999-06-10 Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders

Publications (2)

Publication Number Publication Date
HUP0102203A2 true HUP0102203A2 (hu) 2001-11-28
HUP0102203A3 HUP0102203A3 (en) 2001-12-28

Family

ID=26780365

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102203A HUP0102203A3 (en) 1998-06-15 1999-06-10 Use of optically pure(+)-norcisapride for producing pharmaceutical compositions suitable for treating apnea, bulimia and other disorders

Country Status (26)

Country Link
US (4) US6048879A (hu)
EP (1) EP1089733B1 (hu)
JP (1) JP2002518352A (hu)
KR (3) KR20060017570A (hu)
CN (1) CN1312717A (hu)
AR (1) AR019671A1 (hu)
AT (1) ATE291427T1 (hu)
AU (1) AU4433399A (hu)
BG (1) BG105096A (hu)
BR (1) BR9911299A (hu)
CA (1) CA2333666A1 (hu)
CZ (1) CZ20004737A3 (hu)
DE (1) DE69924375T2 (hu)
ES (1) ES2237110T3 (hu)
HK (1) HK1040058A1 (hu)
HU (1) HUP0102203A3 (hu)
IL (1) IL140118A0 (hu)
IS (1) IS5756A (hu)
NO (1) NO20006357L (hu)
NZ (3) NZ535135A (hu)
PL (1) PL345275A1 (hu)
PT (1) PT1089733E (hu)
SI (1) SI1089733T1 (hu)
SK (1) SK19052000A3 (hu)
TR (7) TR200103056T2 (hu)
WO (1) WO1999065571A2 (hu)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
SK19062000A3 (sk) 1998-06-15 2001-07-10 Sepracor, Inc. Použitie (-)-norcisapridu alebo jeho farmaceuticky prijateľnej soli, v podstate bez jeho (+) stereoizoméru, na liečenie apnoe, bulímie a iných porúch
CA2371822A1 (en) * 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
EP1435238A1 (en) * 1999-03-01 2004-07-07 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
CA2868614A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7844338B2 (en) 2003-02-03 2010-11-30 Enteromedics Inc. High frequency obesity treatment
US7613515B2 (en) * 2003-02-03 2009-11-03 Enteromedics Inc. High frequency vagal blockage therapy
US7167750B2 (en) * 2003-02-03 2007-01-23 Enteromedics, Inc. Obesity treatment with electrically induced vagal down regulation
US20040172084A1 (en) * 2003-02-03 2004-09-02 Knudson Mark B. Method and apparatus for treatment of gastro-esophageal reflux disease (GERD)
US20050070974A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Obesity and eating disorder stimulation treatment with neural block
US20050070970A1 (en) * 2003-09-29 2005-03-31 Knudson Mark B. Movement disorder stimulation with neural block
US7803195B2 (en) * 2004-06-03 2010-09-28 Mayo Foundation For Medical Education And Research Obesity treatment and device
US20060020298A1 (en) * 2004-07-20 2006-01-26 Camilleri Michael L Systems and methods for curbing appetite
US20060020277A1 (en) * 2004-07-20 2006-01-26 Gostout Christopher J Gastric reshaping devices and methods
US7833279B2 (en) * 2004-11-12 2010-11-16 Enteromedics Inc. Pancreatic exocrine secretion diversion apparatus and method
EP1833467B1 (en) 2004-12-20 2016-08-03 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US7672727B2 (en) * 2005-08-17 2010-03-02 Enteromedics Inc. Neural electrode treatment
US7822486B2 (en) * 2005-08-17 2010-10-26 Enteromedics Inc. Custom sized neural electrodes
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
CA2641821C (en) * 2006-02-16 2017-10-10 Imthera Medical, Inc. An rfid-based apparatus, system, and method for therapeutic treatment of a patient
CA2697822A1 (en) 2007-10-09 2009-04-16 Imthera Medical, Inc. Apparatus, system, and method for selective stimulation
BRPI0920548B8 (pt) 2008-10-09 2021-06-22 Imthera Medical Inc aparelho para controlar posição da língua de um paciente
EP2498868A4 (en) 2009-11-10 2013-05-08 Imthera Medical Inc SYSTEM FOR STIMULATING A HYPOGLOSSAL NERVO FOR CONTROLLING THE TONGUE POSITION IN A PATIENT
US8825164B2 (en) 2010-06-11 2014-09-02 Enteromedics Inc. Neural modulation devices and methods
US10123896B2 (en) 2014-03-06 2018-11-13 Mayo Foundation For Medical Education And Research Apparatus and methods of inducing weight loss using blood flow control

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR748807A (fr) * 1932-03-10 1933-07-10 Gulf Refining Co Perfectionnements à la fabrication d'hydrocarbures
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US4962115A (en) * 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5137896A (en) * 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US4598123A (en) * 1983-07-14 1986-07-01 Unites States Steel Corporation Impact modified methyl methacrylate polymer
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4800162A (en) * 1987-04-01 1989-01-24 Sepracor, Inc. Method for resolution of steroisomers in multiphase and extractive membrane reactors
US5057427A (en) * 1988-04-07 1991-10-15 Sepracor, Inc. Method for resolution of stereoisomers
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5075290A (en) * 1989-06-28 1991-12-24 University Of Virginia Alumni Patents Foundation Use of adenosine, adenosine analogs or nucleoside uptake blockers, e.g. dipyridamole, as drug treatments for obstructive sleep apnea and snoring
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5356934A (en) * 1990-03-29 1994-10-18 Eli Lilly And Company Selected serotonin subtype receptor agonist to treat sleep apnea
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
DE69226961T2 (de) * 1991-12-21 1999-04-29 Smithkline Beecham P.L.C., Brentford, Middlesex Verwendung von 5-ht4 - antagonisten zur herstellung eines arzneimittels zur behandlung von harninkontinenz
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
US5407953A (en) * 1994-02-04 1995-04-18 Morgan; Julia A. Treating apnea/hypopnea/snoring in humans
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
FR2735475B1 (fr) * 1995-06-13 1997-07-11 Synthelabo Derives de n-((1,4-diazabicyclo(2.2.2)oct-2-yl)methyl) benzamide, leur preparation et leur application en therapeutique
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
EA002362B1 (ru) * 1997-07-11 2002-04-25 Янссен Фармацевтика Н.В. Применение (+)-4-амино-5-хлор-n-(3-метокси-4-пиперидинил)-2-метоксибензамида для приготовления лекарственных препаратов для лечения заболеваний желудочно-кишечного тракта

Also Published As

Publication number Publication date
ATE291427T1 (de) 2005-04-15
NO20006357L (no) 2001-02-13
SI1089733T1 (en) 2005-06-30
HUP0102203A3 (en) 2001-12-28
WO1999065571A2 (en) 1999-12-23
KR20060067986A (ko) 2006-06-20
US6048879A (en) 2000-04-11
TR200103058T2 (tr) 2002-06-21
US20020147220A1 (en) 2002-10-10
TR200003708T2 (tr) 2001-06-21
KR20010052739A (ko) 2001-06-25
EP1089733B1 (en) 2005-03-23
SK19052000A3 (sk) 2001-06-11
AU4433399A (en) 2000-01-05
US6369079B1 (en) 2002-04-09
IL140118A0 (en) 2002-02-10
TR200103059T2 (tr) 2002-06-21
KR20060017570A (ko) 2006-02-23
EP1089733A2 (en) 2001-04-11
DE69924375T2 (de) 2005-08-11
TR200103056T2 (tr) 2002-06-21
NO20006357D0 (no) 2000-12-13
AR019671A1 (es) 2002-03-13
CZ20004737A3 (cs) 2001-10-17
TR200103054T2 (tr) 2002-06-21
CA2333666A1 (en) 1999-12-23
US6835740B2 (en) 2004-12-28
BG105096A (en) 2002-02-28
CN1312717A (zh) 2001-09-12
PL345275A1 (en) 2001-12-03
ES2237110T3 (es) 2005-07-16
BR9911299A (pt) 2001-03-13
TR200103057T2 (tr) 2002-06-21
DE69924375D1 (de) 2005-04-28
IS5756A (is) 2000-12-08
JP2002518352A (ja) 2002-06-25
NZ526943A (en) 2004-11-26
HK1040058A1 (zh) 2002-05-24
PT1089733E (pt) 2005-08-31
NZ508824A (en) 2003-10-31
US20050154018A1 (en) 2005-07-14
TR200103055T2 (tr) 2002-06-21
NZ535135A (en) 2006-04-28
WO1999065571A3 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
HUP0102203A2 (hu) Optikailag tiszta (+)-norciszaprid alkalmazása apnoé, bulimia és más rendellenességek kezelésére alkalmas gyógyászati készítmények előállítására
Kambalimath et al. Efficacy of 4% Articaine and 2% Lidocaine: A clinical study
NO20003051L (no) Metode for administrering av AspB28-humant insulin
MXPA05008649A (es) Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
HUP0301868A2 (hu) Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz
BR0315319A (pt) Terapias e procedimentos dentais com toxina botulìnica
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
BRPI0417186A (pt) método de tratamento de um indivìduo tendo uma hemoglobinopatia ou uma anemia, de modulação da diferenciação de uma célula-tronco ou precursora de cd34+ para uma linhagem de eritróides, e, composição farmacêutica
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
DE69527966D1 (de) Pharmazeutische zubereitung für die subkutane, intramuskuläre oder intradermale verabreichung von faktor viii
RS20050344A (en) Treatment for hemorrhagic shock
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
ATE353645T1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
HUP0102026A2 (hu) Optikailag tiszta (-)-norciszaprid alkalmazása apnoé, bulimia és más rendellenességek kezelésére szolgáló gyógyszerkészítmények előállítására
NZ328874A (en) Heterocyclic biaryl compounds and their use in pharmaceutical compositions for treatment of dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders
Pandit et al. Comparative evaluation of topical and electronic anesthesia during scaling and root planing
Aminabadi et al. The efficacy of distraction and counterstimulation in the reduction of pain reaction to intraoral injection by pediatric patients
Erdogan et al. Utility of vibratory stimulation for reducing intraoral injection pain
Shetty et al. Comparison of pain perception between computer-controlled local anesthetic delivery and the conventional syringe for inferior alveolar nerve block in children.
BR0201974A (pt) Composição farmacêutica para tratamento de alterações do sono
Romero-Galvez et al. A randomized split-mouth clinical trial comparing pain experienced during palatal injections with traditional syringe versus controlled-flow delivery Calaject technique.
MXPA04007183A (es) Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees